Cargando…

Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience

BACKGROUND: Hypofractionated radiation therapy is a feasible and safe treatment option in elderly and frail patients with glioblastoma. The aim of this study was to evaluate the effectiveness of hypofractionated radiation therapy with concurrent temozolomide in terms of feasibility and disease contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jablonska, Paola Anna, Diez-Valle, Ricardo, Pérez-Larraya, Jaime Gállego, Moreno-Jiménez, Marta, Idoate, Miguel Ángel, Arbea, Leire, Tejada, Sonia, Garcia de Eulate, Maria Reyes, Ramos, Luis, Arbizu, Javier, Domínguez, Pablo, Aristu, José Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553780/ https://www.ncbi.nlm.nih.gov/pubmed/31170245 http://dx.doi.org/10.1371/journal.pone.0217881

Ejemplares similares

Correction: Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience
por: Jablonska, Paola Anna, et al.
Publicado: (2019)

A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
por: Inogés, Susana, et al.
Publicado: (2017)

Erratum to: Factors associated with a higher rate of distant failure after primary treatment for glioblastoma
por: Tejada, Sonia, et al.
Publicado: (2013)

Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications
por: Arbea, Leire, et al.
Publicado: (2010)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

Factors associated with a higher rate of distant failure after primary treatment for glioblastoma
por: Tejada, Sonia, et al.
Publicado: (2013)

Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature
por: Chidley, Phoebe, et al.
Publicado: (2022)

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme
por: Jastaniyah, Noha, et al.
Publicado: (2013)

Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.
por: Rodríguez-Ruiz, María Esperanza, et al.
Publicado: (2012)

Pneumomediastinum as a complication of SABR for lung metastases
por: Rodríguez-Ruiz, María Esperanza, et al.
Publicado: (2015)

Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
por: Zhong, Liangzhi, et al.
Publicado: (2019)

(18)F-FDG-PET Imaging Patterns in Autoimmune Encephalitis: Impact of Image Analysis on the Results
por: Moreno-Ajona, David, et al.
Publicado: (2020)

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
por: Ciammella, Patrizia, et al.
Publicado: (2013)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era
por: Carico, Christine, et al.
Publicado: (2012)

Tbx2 confers poor prognosis in glioblastoma and promotes temozolomide resistance with change of mitochondrial dynamics
por: Yi, Fuxin, et al.
Publicado: (2017)

Retraction: Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study
por: Damato, Anna R, et al.
Publicado: (2021)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Technical flaws in multiple-choice questions in the access exam to medical specialties (“examen MIR”) in Spain (2009–2013)
por: Rodríguez-Díez, María Cristina, et al.
Publicado: (2016)

Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma
por: Lee, I-Neng, et al.
Publicado: (2021)

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
por: Oike, Takahiro, et al.
Publicado: (2013)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
por: Hata, Nobuhiro, et al.
Publicado: (2019)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report
por: Martin-Romano, P., et al.
Publicado: (2017)

Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer
por: Jablonska, Paola Anna, et al.
Publicado: (2021)

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Relation between autophagy and the resistence of glioblastoma cells to temozolomide
por: Carmo, Anália, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_acf47vrdcs7norfckv3t96gi50